AZD1390

AZD1390 is an ATM inhibitor.

Signaling Pathways >> Cell Cycle/DNA Damage >> ATM/ATR

Signaling Pathways >> PI3K/Akt/mTOR >> ATM/ATR

Research Areas >> Cancer

Research Areas >> Inflammation/Immunology

ATM

Median survival of mice treated with AZD1390 and radiation are significantly longer than untreated control mice (p=0.001). No overt signs of treatment toxicity are observed with small animal radiation research platform (SARRP) contrary to wholehead irradiated mice that seem to develop mucositis and difficulties drinking and eating at doses >10 Gy in combination with AZD1390[2].

Mouse GL261 glioma (p53 mutant) cells are implanted intra-cranially into immunocompetent, syngeneic C57/bl6 mice followed by bioluminescent imaging (BLI) prior to randomization. AZD1390 is administered by oral gavage prior to deliver multiple fractions of 2-3 Gy of radiation on 2 to 4 consecutive days. Radiation is administered via small animal radiation research platform (SARRP) irradiation to the site of the tumor with a 5×5 mm lateral field[2].

[1]. Delivering our pipeline through scientific leadership. Innovative Medicines & Early Development Biotech Unit 2016.

[2]. J. Kahn, et al. Next-Generation ATM Kinase Inhibitors Under Development Radiosensitize Glioblastoma With Conformal Radiation in a Mouse Orthotopic Model. IJROBP. 2017. 99, 600-601.

Wortmannin | Ceralasertib(AZD6738) | Berzosertib (VE-822) | KU55933 (ATM Kinase Inhibitor) | VE-821 | AZD-0156 | KU 60019 | AZ20 | CP-466722 | CGK 733 | ETP-46464 | KU 59403